Vistusertib - AstraZeneca

Drug Profile

Vistusertib - AstraZeneca

Alternative Names: AZD 2014

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Cambridge University Hospitals; Massachusetts General Hospital; National Cancer Institute (USA); Netherlands Cancer Institute; NHS Greater Glasgow and Clyde; Queen Mary University of London; Samsung Medical Center; University of Birmingham; University of London; University of Texas M. D. Anderson Cancer Center
  • Class 2 ring heterocyclic compounds; Antineoplastics; Benzamides; Cytostatics; Morpholines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Colorectal cancer; Diffuse large B cell lymphoma; Gastric cancer; Meningioma; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer; Solid tumours
  • Phase I/II Fallopian tube cancer; Glioblastoma; Peritoneal cancer
  • No development reported Prostate cancer
  • Discontinued Renal cancer

Most Recent Events

  • 28 Oct 2018 No recent reports of development identified for phase-I development in Prostate-cancer(Early-stage disease, Neoadjuvant therapy) in United Kingdom (PO, Tablet)
  • 18 Sep 2018 AstraZeneca terminates the phase II SUKSES-D trial based on decision of IP support organisation in Small cell lung cancer (Monotherapy, Second-line therapy or greater) in South Korea (PO) (NCT03106155)
  • 27 Aug 2018 Additioanl efficacy data from a phase I trial in Solid tumours released by the Institute of Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top